Yamamoto, HS, Xu, Q and Fichorova, RN BMC Microbiol. 2013 Jan 8;13:4. doi: 10.1186/1471-2180-13-4.
Synopsis: Preclinical studies of Osel’s engineered live biotherapeutic for prevention of HIV infection in women demonstrated successful in vitro production of the anti-HIV protein without inducing cellular toxicity and without altering levels of cytokines. These studies suggest that Osel’s live biotherapeutic is safe. These studies were performed in an independent collaborating laboratory at Harvard University.